solifenacin succinate

Known as: Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate, Solifenacin Succinate [Chemical/Ingredient], Succinate, Solifenacin 
A quinuclidine and tetrahydroisoquinoline derivative and selective M3 MUSCARINIC ANTAGONIST. It is used as a UROLOGIC AGENT in the treatment of… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND Combining the β3-adrenoceptor agonist mirabegron and the antimuscarinic (AM) agent solifenacin may improve efficacy in… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 4
Is this relevant?
2015
2015
BACKGROUND Short-term trials have demonstrated the efficacy and safety of combination therapy using antimuscarinics and… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2007
2007
Solifenacin succinate [YM905; (3R)-1-azabicyclo[2.2.2]oct-3-yl(1S)-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
OBJECTIVE To compare two new generation antimuscarinics at their recommended doses for treatment of overactive bladder syndrome… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
OBJECTIVE To examine safety and tolerability findings as primary endpoints, and efficacy outcomes as secondary endpoints, of… (More)
Is this relevant?
2005
2005
OBJECTIVE To assess the effect of solifenacin succinate treatment on quality of life (QoL) measured in clinical trials in… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
PURPOSE In this phase 3 trial we assessed the efficacy of solifenacin 5 mg and 10 mg daily in patients with symptoms related to… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
OBJECTIVE To assess in a phase 3a trial the efficacy of solifenacin succinate, a once-daily oral antimuscarinic agent in… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
OBJECTIVES To evaluate the dose-response relationship and safety/tolerability of solifenacin succinate (YM905) in the treatment… (More)
Is this relevant?
2004
2004
The pharmacokinetic profile of solifenacin succinate (YM905; Vesicare), a new once-daily bladder-selective muscarinic receptor… (More)
Is this relevant?